Clinical Trials
7 trialsNCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT06788171 2025-01-23
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06463834 2024-06-18
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Recruiting
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT05207735 2022-01-26
SCRCA
Henan Cancer Hospital
Phase 2 Unknown
NCT04089657 2019-09-13
ASGARD
Fujian Cancer Hospital
Phase 2 Unknown